LONDON, UNITED KINGDOM / ACCESS Newswire / May 15, 2025 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company"), the only publicly listed longevity company in Europe, announces ...

LONDON - Genflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF), a biotechnology firm focused on longevity gene therapies, has reached a pivotal stage in the patent process for its SIRT6 gene variants ...

Although it is claimed that when one eats less, one lives longer, this special rodent is, in fact, chubby and thanks to its expression of the SIRT6 (sirtuin) protein at high levels – they age ...

Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced ...

Genflow Biosciences plc has announced a development program in ophthalmology focused on advancing a novel gene therapy leveraging its proprietary centenarian SIRT6 (cSIRT6).

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: ...

This collaboration comes as Genflow actively works on a 12-month proof-of-concept clinical trial for their SIRT6-centenarian gene therapy in aged dogs, which began in March 2025. Additional ...

The application, titled "Variants of SIRT6 for Use in Preventing and/or Treating Age-Related Diseases," was originally filed on 13 May 2022 and is jointly owned by the University of Rochester ...

Two abstracts discussing Immunic's phase 1/1b clinical trial of IMU-856, an orally available and systemically acting small molecule modulator that targets SIRT6 (Sirtuin 6), in patients with ...